Morgan Hakki

Oregon Health & Science University — United States

Medicine · Health Sciences

25h-index2.5kcitations60works2.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cytomegalovirus and herpesvirus research(28), Herpesvirus Infections and Treatments(19), Antibiotic Resistance in Bacteria(18), Neutropenia and Cancer Infections(16), Antifungal resistance and susceptibility(6)

Publications60 total

Investigational treatments for cytomegalovirus infection in phase I and II study
Expert Opinion on Investigational Drugs·2025
American Society for Transplantation and Cellular Therapy Series #11: Updated Cytomegalovirus Guidelines in Hematopoietic Cell Transplant and Cellular Therapy Recipients
Transplantation and Cellular Therapy·2025· 8 citedOpen Access
Role of R5 pyocin in the predominance of high-risk Pseudomonas aeruginosa isolates
Microbiological Research·2025Open Access
P-2304. Prevalence and clinical features of cefepime heteroresistance among bloodstream isolates of Pseudomonas aeruginosa in patients with hematologic malignancy
Open Forum Infectious Diseases·2025Open Access
P-2320. Clinical Significance of Colonization with Fluoroquinolone-Resistant Enterobacterales in Hematopoietic Cell Transplant Recipients and Patients with Acute Leukemia
Open Forum Infectious Diseases·2025· 1 citedOpen Access
Role of R5 Pyocin in the Predominance of High-Risk <i>Pseudomonas aeruginosa</i> Isolates
2024· 1 citedOpen Access
Cefiderocol heteroresistance associated with mutations in TonB-dependent receptor genes in <i>Pseudomonas aeruginosa</i> of clinical origin
Antimicrobial Agents and Chemotherapy·2024· 15 citedOpen Access
The impact of an intervention to reduce dispersal from wastewater drain sites on carbapenem-resistant <i>Pseudomonas aeruginosa</i> colonization and bloodstream infection on a hematopoietic cell transplant and hematologic malignancy unit
Infection Control and Hospital Epidemiology·2024· 2 cited
Cefiderocol heteroresistance associated with mutations in TonB-dependent receptor genes in <i>Pseudomonas aeruginosa</i> of clinical origin
2024· 2 citedOpen Access
Real-Life Use of Ceftolozane/Tazobactam for the Treatment of Bloodstream Infection Due to Pseudomonas aeruginosa in Neutropenic Hematologic Patients: a Matched Control Study (ZENITH Study)
UNC Libraries·2024Open Access
Case Commentary: Successful Use of Cefepime/Zidebactam (WCK 5222) as a Salvage Therapy for the Treatment of Disseminated Extensively Drug-Resistant New Delhi Metallo-β-Lactamase-Producing <i>Pseudomonas aeruginosa</i> Infection in an Adult Patient with Acute T-Cell Leukemia
Antimicrobial Agents and Chemotherapy·2023· 2 citedOpen Access
<i>Pseudomonas aeruginosa</i> ExoU-associated virulence in HCT recipients and patients with hematologic malignancies
Blood Advances·2023Open Access
Educational Needs Assessment of US Healthcare Practitioners Managing Cytomegalovirus Infection in Hematopoietic Stem Cell Transplant Recipients: Results from a Survey Using a Simulated Case Scenario
Transplantation and Cellular Therapy·2023Open Access
New Perspectives on Antimicrobial Agents: Isavuconazole
Antimicrobial Agents and Chemotherapy·2022· 77 citedOpen Access
Long-Term Dominance of Carbapenem-Non-Susceptible Pseudomonas aeruginosa ST111 in Hematologic Malignancy Patients and Hematopoietic Cell Transplant Recipients
Frontiers in Cellular and Infection Microbiology·2022· 9 citedOpen Access
Real-Life Use of Ceftolozane/Tazobactam for the Treatment of Bloodstream Infection Due to Pseudomonas aeruginosa in Neutropenic Hematologic Patients: a Matched Control Study (ZENITH Study)
Microbiology Spectrum·2022· 29 citedOpen Access
803. The Impact of Bundled Interventions to Decrease Transmission of Drug-Resistant <i>Pseudomonas aeruginosa</i> from Wastewater Drain Sites on a Hematologic Malignancy/Hematopoietic Stem Cell Transplant Unit
Open Forum Infectious Diseases·2021Open Access
American Society for Transplantation and Cellular Therapy Series: #3—Prevention of Cytomegalovirus Infection and Disease After Hematopoietic Cell Transplantation
Transplantation and Cellular Therapy·2021· 112 cited
Emergence of non-susceptibility during persistent <i>Pseudomonas aeruginosa</i> bacteraemia in haematopoietic cell transplant recipients and haematological malignancy patients
JAC-Antimicrobial Resistance·2021· 3 citedOpen Access
Letermovir treatment of cytomegalovirus infection or disease in solid organ and hematopoietic cell transplant recipients
Transplant Infectious Disease·2021· 67 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Michael Boeckh(7), Adam P. Geballe(6), James S. Lewis(6), Sunwen Chou(5), Samuel A. Shelburne(5), Per Ljungman(4), Lynne Strasfeld(4), Katherine L. De Niro(3), Genovefa A. Papanicolaou(3), Lauren Fontana(3), Stephanie L Egge(3), Liyang Zhang(3), Filemon C. Tan(3), Natalia V. Kirienko(3), Lawrence Corey(2), Lara Danziger‐Isakov(2), Paul A. Carpenter(2), Roy F. Chemaly(2), Emily E. Marshall(2), Ajit P. Limaye(2)